<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Early pregnancy prediction of preeclampsia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Early pregnancy prediction of preeclampsia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Early pregnancy prediction of preeclampsia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Errol R Norwitz, MD, PhD, MBA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Federica Bellussi, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Preeclampsia is a multi-system progressive disorder characterized by the new onset of hypertension and significant end-organ dysfunction with or without proteinuria, in the last half of pregnancy or postpartum  (<a class="graphic graphic_table graphicRef79977" href="/d/graphic/79977.html" rel="external">table 1</a>). The genesis of the disease is laid down in early pregnancy and is characterized anatomically by abnormal remodeling of the maternal spiral arteries at the placental site.</p><p>Patients at high risk for developing preeclampsia may benefit from the initiation of low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (LDA) therapy starting at the end of the first trimester, as this may reduce the frequency of preeclampsia and associated maternal and perinatal morbidity and mortality. We base high-risk status on obstetric and medical risk factors rather than laboratory and imaging tests because we believe that the results of these tests in early pregnancy do not accurately distinguish patients who will go on to develop preeclampsia from those who will not (ie, the positive predictive value is low) [<a href="#rid1">1-3</a>]. In addition to assessment of risk factors, early clinical detection of the disease is important. All pregnant patients should be monitored for evidence of preeclampsia at each prenatal visit. Early diagnosis may improve maternal and perinatal outcomes by ensuring appropriate management (eg, antenatal corticosteroids for fetal lung maturation, treatment of severe hypertension, <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">magnesium sulfate</a> to prevent seizures, and early delivery).</p><p>This topic will discuss available data regarding screening in early pregnancy to identify patients most likely to develop preeclampsia. Additional issues related to the diagnosis, management, and prevention of preeclampsia are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL APPROACH</span></p><p class="headingAnchor" id="H4108061536"><span class="h2">Routine regular prenatal blood pressure measurement</span><span class="headingEndMark"> — </span>We agree with the assessment of the United States Preventive Services Task Force (USPSTF) that all pregnant individuals are at risk for preeclampsia and should be screened by measurement of blood pressure at all provider visits throughout pregnancy [<a href="#rid4">4</a>]. Although preeclampsia is not diagnosed before 20 weeks of gestation, early measurements establish the patient's baseline blood pressure. In a systematic review, blood pressure ≥140/90 mmHg before 20 weeks was a good predictor of preeclampsia occurrence (positive likelihood ratio 5.95 versus &lt;3 for 120/80 and 130/80), but blood pressures &lt;120/80 mmHg, &lt;130/80 mmHg, and &lt;140/90 mmHg were not predictive of absence of preeclampsia occurrence (negative likelihood ratio &gt;0.2) [<a href="#rid5">5</a>]. In another systematic review, a hypertensive disorder of pregnancy developed in 11.6 percent of patients with blood pressures of 120-139/80-89 mmHg and 5.6 percent of those with blood pressures lower than 120/80 mmHg before 20 weeks of gestation [<a href="#rid6">6</a>].</p><p>The USPSTF assessment was based on the following principles and evidence: blood pressure can be readily and accurately measured, measurement of blood pressure is not harmful, and recognition and treatment of preeclampsia can reduce maternal and perinatal morbidity and mortality [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H3498824244"><span class="h2">Identify high-risk pregnancies early in gestation</span><span class="headingEndMark"> — </span>Pregnant individuals should be evaluated early in pregnancy for risk factors for preeclampsia  (<a class="graphic graphic_table graphicRef61266" href="/d/graphic/61266.html" rel="external">table 2</a>). By quantifying the risk of preeclampsia conferred by various individual clinical and demographic risk factors, the clinician is better equipped to estimate a patient's risk of preeclampsia and whether they are a candidate for heightened pregnancy surveillance and/or prophylactic measures (low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> [LDA]). In the United States, the US Preventive Services Task Force criteria for patients at high risk of developing preeclampsia are commonly used for quantifying risk and selecting candidates for LDA [<a href="#rid8">8</a>]. In the United Kingdom, the National Institute for Health and Care Excellence (NICE) developed a similar list [<a href="#rid9">9</a>]. During the pandemic, infection with SARS-CoV-2 in pregnancy was also associated with an increased risk of preeclampsia [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Selecting patients at high risk of developing preeclampsia'</a> and  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Timing of initiation'</a> and  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Dose'</a>.)</p><p>Early assessment is particularly important for individuals who are planning to receive pregnancy care and give birth in a low-risk setting (eg, midwifery practice, birthing center, home birth), which would be contraindicated if preeclampsia develops. These patients, if identified as high risk for development of preeclampsia, should be offered consultation with a physician with expertise in the management of the disease [<a href="#rid11">11,12</a>].</p><p>In a meta-analysis of cohort studies including ≥1000 patients that evaluated the risk of preeclampsia in relation to common clinical risk factors assessed at ≤16 weeks of gestation (92 studies, &gt;25 million pregnancies), the highest rate of preeclampsia occurred in patients with antiphospholipid syndrome (pooled rate 17.3 percent, pooled relative risk [RR] 2.8), and the highest relative risk of preeclampsia occurred in patients with a past history of the disease (pooled rate 12 percent, pooled RR 8.4) [<a href="#rid13">13</a>]. Other prominent risk factors included chronic hypertension (pooled rate 16.0 percent, pooled RR 5.1), preexisting (pregestational) diabetes (pooled rate 11.0 percent, pooled RR 3.7), prepregnancy BMI &gt;30 kg/m<sup>2</sup> (pooled rate 7.1 percent, pooled RR 2.8), multifetal pregnancy (pooled rate 6.4 percent, pooled RR 2.9), and use of assisted reproductive technology (pooled rate 6.2 percent, pooled RR 1.8).</p><p>Because historical risk factors only predict approximately 30 percent of patients who will develop preeclampsia [<a href="#rid14">14</a>], use of laboratory and imaging tests in combination with historical risk factors to calculate a patient's risk of developing preeclampsia is an active area of investigation. (See <a class="local">'Investigational approaches'</a> below.)</p><p>However, current risk prediction models have low positive predictive value, thus potentially worrying a large number of pregnant individuals about a disorder they will not develop and exposing them to tests and interventions that will not benefit them [<a href="#rid3">3,15</a>]. One reason for the low predictive value may be insufficiently accounting for factors that mitigate risk, such as a previous normotensive pregnancy. Another reason may involve not distinguishing between early-onset and late-onset preeclampsia, which have different risk profiles and recurrence rates. (See <a class="local">'Risk prediction models'</a> below.)</p><p class="headingAnchor" id="H3173286781"><span class="h3">Prenatal care for patients identified as high risk</span><span class="headingEndMark"> — </span>In addition to routine prenatal care and LDA, performing the following assessments early in pregnancy in patients who are at high risk of developing preeclampsia can be helpful later in gestation in distinguishing preeclampsia from underlying disorders associated with similar clinical and laboratory findings: </p><p class="bulletIndent1"><span class="glyph">●</span>Accurate determination of gestational age</p><p class="bulletIndent1"><span class="glyph">●</span>Baseline blood pressure</p><p class="bulletIndent1"><span class="glyph">●</span>Baseline laboratory values – platelet count, creatinine concentration, liver chemistries, and urinary protein [protein:creatinine ratio or 24-hour urine protein])</p><p></p><p>(See  <a class="medical medical_review" href="/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis", section on 'Differential diagnosis'</a>.)</p><p>It is also prudent to educate high-risk patients about the signs and symptoms of preeclampsia and monitor them more closely, particularly for increases in blood pressure, as patients with second-trimester systolic pressures 120 to 129 mmHg and diastolic 80 to 90 mmHg are at increased risk for developing preeclampsia [<a href="#rid16">16</a>]. Blood pressure measurement at each prenatal visit appears to be as reliable as self-monitored blood pressure for early detection of preeclampsia. In two large randomized trials comparing the effect of self-monitoring blood pressure versus usual care during pregnancy, self-monitoring with telemonitoring did not result in significantly earlier office-based detection of hypertension or in lower incidence of severe hypertension or preeclampsia [<a href="#rid17">17,18</a>]. One trial included patients with chronic or gestational hypertension and the other included patients at higher-risk for developing preeclampsia except those with chronic or gestational hypertension. Approximately 30 percent of the participants had discordancy between the home and office readings, most of which were attributed to white coat hypertension. These patients may benefit from self-monitoring to avoid unnecessary escalation of evaluation and treatment.</p><p class="headingAnchor" id="H830566426"><span class="h2">Interventions to reduce risk</span><span class="headingEndMark"> — </span>Most risk factors for preeclampsia are not modifiable, but avoiding prepregnancy obesity, excessive gestational weight gain, and multifetal pregnancies in the setting of treatment of infertility are notable exceptions. </p><p class="bulletIndent1"><span class="glyph">●</span>Patients with obesity can reduce their risk of developing preeclampsia by losing weight before pregnancy. Bariatric surgery may be an option for those with severe obesity. (See  <a class="medical medical_review" href="/d/html/433.html" rel="external">"Obesity in pregnancy: Complications and maternal management", section on 'Preconception counseling, evaluation, and care'</a> and  <a class="medical medical_review" href="/d/html/411.html" rel="external">"Fertility and pregnancy after bariatric surgery", section on 'Preeclampsia and other hypertensive disorders of pregnancy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with and without obesity may reduce their risk of developing preeclampsia by not exceeding Institute of Medicine (now National Academy of Medicine) recommendations for gestational weight gain  (<a class="graphic graphic_table graphicRef75820" href="/d/graphic/75820.html" rel="external">table 3</a>) [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/d/html/441.html" rel="external">"Gestational weight gain", section on '2009 IOM weight gain recommendations'</a> and  <a class="medical medical_review" href="/d/html/441.html" rel="external">"Gestational weight gain", section on 'Overweight and obese pregnant people'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>LDA (81to 150 mg daily) is the only drug for which there is proven evidence of benefit in reducing the risk of preeclampsia when administered throughout the second and third trimesters in patients at high risk. For patients at low risk for developing preeclampsia, available evidence does not support LDA use for prevention of preeclampsia, but a modest (approximately 10 percent) reduction in the risk of preeclampsia and its sequelae (growth restriction, preterm birth) is possible for patients at moderate-to-high risk of developing the disease. The evidence for this approach is reviewed separately. (See  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Candidates'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients undergoing infertility therapy with in vitro fertilization or ovulation induction alone, various techniques can be employed to reduce the chances of multiple gestation. (See  <a class="medical medical_review" href="/d/html/7417.html" rel="external">"Strategies to control the rate of high order multiple gestation", section on 'Limiting the multiple gestation risk of assisted reproductive technology'</a> and  <a class="medical medical_review" href="/d/html/7417.html" rel="external">"Strategies to control the rate of high order multiple gestation", section on 'Limiting the multiple gestation risk of ovulation induction and superovulation'</a>.)</p><p></p><p>Many agents other than LDA have been studied for preeclampsia risk reduction (eg, calcium, <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> and C, antioxidants, omega 3 fatty acids, heparin), but the data do not show significant or consistent evidence of benefit across populations. These data are reviewed separately. (See  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention"</a>.)</p><p class="headingAnchor" id="H980887592"><span class="h1">INVESTIGATIONAL APPROACHES</span></p><p class="headingAnchor" id="H144643848"><span class="h2">Screening tests</span><span class="headingEndMark"> — </span>We do not use blood or imaging tests to screen for preeclampsia. Based on data from patients with established preeclampsia, a wide variety of laboratory and imaging tests have been proposed to detect subgroups of individuals at high risk of developing the disease. Because the prevalence of preeclampsia in the general obstetric population is relatively low (1 to 7 percent), a test would need very high sensitivity and specificity to accurately predict or exclude the development of the disease. Systematic reviews and expert opinion of studies that evaluated clinically available tests have generally concluded that these tests are not sufficiently accurate (high sensitivity and specificity) for screening the general obstetric population and that the overall methodologic quality of available studies was generally poor [<a href="#rid7">7,20-28</a>]. For this reason, the American College of Obstetricians and Gynecologists recommends taking a detailed medical history and assessing blood pressure to assess a patient's risks for developing preeclampsia [<a href="#rid3">3</a>], as described above. (See <a class="local">'Clinical approach'</a> above.)</p><p>The utility of systematic reviews of tests for prediction of preeclampsia has been limited by several factors, including (1) variation in the definition of preeclampsia, which introduces heterogeneity in the classification of the syndrome; (2) variation in inclusion/exclusion criteria, which also increases heterogeneity; (3) variation in the criteria defining level of risk (low versus high) of a given population (some studies of low-risk populations have had preeclampsia incidence rates higher than high-risk populations in other studies); (4) multiplicity of potential tests, test combinations, and timing of screening during pregnancy; (5) lack of inclusion of specific important information; and (6) flawed study design and/or conduct [<a href="#rid29">29,30</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Biomarkers</span></p><p class="headingAnchor" id="H2578005277"><span class="h4">Angiogenic modulators</span><span class="headingEndMark"> — </span>Data from both human and animal models suggest that aberrant expression of angiogenic modulators is important in the pathogenesis of diffuse endothelial injury and increased capillary permeability, which are the pathophysiologic hallmarks of preeclampsia. The angiogenic factors of interest include vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), as well as two anti-angiogenic proteins, soluble endoglin (sEng) and the truncated form of the full-length VEGF receptor type-1 (Flt-1), known as soluble fms-like tyrosine kinase 1 (sFlt-1). </p><p>Ischemic trophoblast, which is a characteristic finding in preeclampsia, increases production of anti-angiogenic proteins (sEng, sFlt-1) and reduces production of angiogenic proteins (VEGF, PlGF). Alterations in absolute levels of VEGF [<a href="#rid31">31-34</a>], PlGF [<a href="#rid31">31,32</a>], sFlt-1 [<a href="#rid31">31,32,35-41</a>], and sEng [<a href="#rid37">37-40,42</a>] in maternal blood and urine precede the onset of clinical preeclampsia by several weeks to months, correlate with disease severity, and normalize after delivery. (See  <a class="medical medical_review" href="/d/html/6760.html" rel="external">"Preeclampsia: Pathogenesis", section on 'sFlt-1, VEGF, PlGF'</a> and  <a class="medical medical_review" href="/d/html/6760.html" rel="external">"Preeclampsia: Pathogenesis", section on 'Soluble endoglin'</a>.)</p><p>Combined models that include angiogenic markers and maternal factors in asymptomatic patients in the second trimester provide the best performance for predicting early preeclampsia. In contrast, levels of angiogenic markers in asymptomatic patients early in pregnancy (first and early second trimesters) are not clinically useful for predicting future development of preeclampsia because the deviation of sFlt-1 levels in patients with preeclampsia can only be detected at ≥22.5 weeks of gestation and the lower PlGF levels in patients with preeclampsia is detected at ≥17 weeks [<a href="#rid43">43</a>]. For example, a nested case-control study [<a href="#rid44">44</a>] evaluated urine PlGF to predict preeclampsia using stored urine specimens from participants who had been enrolled in the Calcium for Preeclampsia Prevention trial [<a href="#rid45">45</a>], which included healthy nulliparous individuals with singleton pregnancies followed from 13 to 21 weeks of gestation until 24 hours postpartum. Urine samples were collected before enrollment, at 26 to 29 weeks of gestation, at 36 weeks, and at onset of preeclampsia. Baseline urinary PlGF levels early in pregnancy (8 to 21 weeks of gestation) were not significantly different between patients who developed preeclampsia and those who remained normotensive. However, the test was predictive of preeclampsia late in gestation. Patients who went on to develop preeclampsia had lower levels of PlGF than controls at each sampling interval from 25 weeks through onset of disease. At 21 to 32 weeks, a PlGF concentration in the lowest quartile (less than 118 pg/mL) was highly predictive of development of preterm preeclampsia (OR 22.5, 95% CI 7.4-67.8) but less predictive of term preeclampsia (OR 2.2, 95% CI 1.2-4.3). </p><p class="headingAnchor" id="H2308734915"><span class="h4">Other laboratory tests</span><span class="headingEndMark"> — </span>Maternal serum analyte testing is an important component of Down syndrome screening programs. Increasing evidence suggests that unexplained abnormal maternal serum analyte concentrations (eg, pregnancy-associated plasma protein A [PAPP-A]), as well as abnormalities in circulating cell-free DNA and micro-RNA levels, in the first and second trimesters are also predictive of adverse pregnancy outcomes, including preeclampsia [<a href="#rid46">46-54</a>]. These associations are not sufficiently strong to warrant changes in routine prenatal care, but the biomarkers have been used in risk prediction models.</p><p class="headingAnchor" id="H7"><span class="h3">Uterine artery Doppler velocimetry</span><span class="headingEndMark"> — </span>Although meta-analyses show that uterine artery Doppler analysis can predict patients at increased risk of preeclampsia [<a href="#rid55">55-57</a>], we and most experts recommend not performing these studies for screening in early pregnancy [<a href="#rid21">21,58-61</a>]. The false-positive rate is quite high [<a href="#rid60">60,61</a>], leading to excessive patient anxiety and health care costs.</p><p>Impedance to flow in the uterine arteries normally decreases as pregnancy progresses. Increased impedance for gestational age is an early radiographic feature of preeclampsia and likely reflects high downstream resistance due to defective differentiation of trophoblast, which leads to defective invasion of spiral arteries and failure of these vessels to transform into low resistance vessels.</p><p>Two types of uterine artery Doppler waveform analysis techniques have emerged for prediction of preeclampsia, as well as other disorders associated with impaired placentation (eg, fetal growth restriction, pregnancy loss): (1) presence or absence of diastolic notching (unilateral, bilateral) of the uterine arcuate vessels and (2) flow waveform ratios (eg, high resistance or pulsatility index, systolic/diastolic ratio).</p><p>The use of uterine artery Doppler velocimetry for prediction of preeclampsia was best illustrated in a systematic review of 74 studies including almost 80,000 participants [<a href="#rid55">55</a>]. These studies involved 15 uterine artery Doppler indices and patients at either low or high risk of developing preeclampsia. Uterine artery Doppler ultrasonography was more accurate for prediction of preeclampsia when performed in the second trimester than in the first trimester. In patients at high risk of developing preeclampsia, the overall risk of preeclampsia was best predicted by second-trimester elevation of pulsatility index accompanied by uterine artery notching (sensitivity 19 percent, specificity 99 percent, positive likelihood ratio [+LR] 21, negative likelihood ratio [-LR] 0.82), and the risk of severe preeclampsia was best predicted by second-trimester elevated resistance index (sensitivity 80 percent, specificity 78 percent, +LR 3.7, -LR 0.26).</p><p>Studies of uterine artery Doppler velocimetry for prediction of preeclampsia are difficult to compare because investigators have used different Doppler sampling techniques, definitions of abnormal flow velocity waveform, populations, gestational age at examination, and criteria for the diagnosis of preeclampsia. Typically, uterine artery Doppler findings are not interpreted alone, but rather in combination with other clinical/demographic risk factors, serum biomarkers, and other ultrasound measurements such as 3-dimensional placental volumes. There are also increasing data evaluating uterine blood flow by magnetic resonance imaging and other more sophisticated technologies.</p><p class="headingAnchor" id="H8"><span class="h2">Risk prediction models</span><span class="headingEndMark"> — </span>As described above, specific maternal characteristics, Doppler ultrasound findings, and biomarkers in blood are associated with an increased risk of preeclampsia. Traditionally, each risk factor is treated as a separate screening test, and a higher number of risk factors is assumed to carry a higher risk for development of preeclampsia.</p><p>Multiple investigators have used these variables in logistic regression analysis to create a tool to predict an individual patient's risk of developing preeclampsia while they are still early in pregnancy (eg, Fetal Medicine Foundation [FMF] risk for preeclampsia calculator [<a href="#rid62">62</a>]). In validation studies, the detection rate of the FMF London and Fetal Medicine Barcelona combined first-trimester screening algorithms for prediction of preterm preeclampsia ranged from 75 to 92 percent at screen-positive rate of 10 percent [<a href="#rid63">63</a>]. In one of the validation datasets, 90 percent of cases of preeclampsia cases &lt;34 weeks and 75 percent of cases &lt;37 weeks were predicted. Ideally, patients identified as high risk would be encouraged to address any modifiable risk factors; educated about the signs and symptoms of preeclampsia, so they will notify their provider as soon as clinical manifestations occur; and followed with more frequent office visits. Some clinicians also start these patients on low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (LDA). (See  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Candidates'</a>.)</p><p>The utility of prescribing <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> based on risk determined by these tools rather than historic and demographic risk factors has not been studied extensively. A meta-analysis found that first-trimester screening algorithms for preeclampsia coupled with early initiation of aspirin 150 mg daily reduced the prevalence of preeclampsia before 37 weeks by 39 percent (0.45 versus 0.70 percent; OR 0.61, 95% CI 0.52-0.70), with a 62 percent reduction of preeclampsia before 32 to 34 weeks (0.14 versus 0.41 percent; OR 0.38, 95% CI 0.22-0.64), compared with usual care [<a href="#rid64">64</a>]. The results were consistent across the six observational studies and one large randomized trial [<a href="#rid65">65</a>]. </p><p>Although the screen-positive rate may be lower and the positive likelihood ratio may be higher than with traditional risk factor-based models [<a href="#rid66">66</a>], these tools still have relatively low positive likelihood ratios, so many patients will be made anxious and receive unnecessary treatment for a small absolute risk reduction. Furthermore, the tools typically require determination of mean arterial pressure, a Doppler ultrasound examination at 11 to 13 weeks for uterine artery pulsatility index, specific expertise by the sonographer, additional laboratory testing (eg, serum PAPP-A and serum placental growth factor), and, in turn, additional costs and complicated logistics for implementation. In addition, methodologic deficiencies are common, which limit their reliability and validity. For example, a systematic review evaluated 24 studies of 38 predictive models that included uterine artery Doppler as one of the independent variables [<a href="#rid30">30</a>]. The median number of study participants was 697, the median number of cases of preeclampsia per model was 37, and the median number of risk predictors was 5. Almost one-quarter of the models had fewer than 10 events per predictor of preeclampsia, and almost 95 percent had fewer than 10 events per predictor of early preeclampsia. Only one model adequately described treatment and handling of missing data, and only three models reported model validation. </p><p class="headingAnchor" id="H9"><span class="h1">SCREENING TESTS NOT USEFUL FOR PREDICTING PREECLAMPSIA</span></p><p class="headingAnchor" id="H10"><span class="h2">Provocative biophysical tests</span><span class="headingEndMark"> — </span>Aberrations in vascular responsiveness have formed the basis of several screening tests for the detection of pregnant individuals at risk for preeclampsia. None of these tests (angiotensin II challenge test [<a href="#rid67">67,68</a>], roll-over test [supine pressor test] [<a href="#rid68">68,69</a>], isometric exercise test [hand-grip test] [<a href="#rid70">70,71</a>]) are currently being used clinically because they are expensive, time-consuming, and, most importantly, unreliable.</p><p class="headingAnchor" id="H11"><span class="h2">Serum uric acid</span><span class="headingEndMark"> — </span>Although hyperuricemia is commonly seen in patients with preeclampsia, a systematic review of five studies concluded that measurement of serum uric acid concentration before 25 weeks of gestation was not useful for predicting which individuals would develop preeclampsia [<a href="#rid72">72</a>]. One study used a rise in serum uric acid concentration above baseline level as the criterion for a positive test result, while the other four studies used threshold values above 3.5 to 4 mg/dL (0.21 to 0.24 mmol/L) as the cut-off for a positive test. Sensitivities ranged from 0 to 56 percent and specificities ranged from 77 to 95 percent. The data were not pooled because of the methodologic uncertainties and the clinical differences between studies [<a href="#rid72">72</a>].</p><p>Similarly, a second systematic review concluded that serum uric acid measurement was not useful for predicting development of complications in patients with preeclampsia [<a href="#rid73">73</a>], although it may be useful in predicting the length of the latency period from diagnosis to delivery [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Screening for inherited thrombophilias</span><span class="headingEndMark"> — </span>The weight of evidence, including data from prospective cohort studies [<a href="#rid75">75,76</a>], indicates that inherited thrombophilias (such as Factor V Leiden mutation, prothrombin gene mutation, protein C or S deficiency, and antithrombin deficiency) are not associated with preeclampsia; therefore, screening pregnant individuals for inherited thrombophilias is not useful for predicting those at high risk of developing the disease. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy", section on 'Selection of patients for testing'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Screening for antiphospholipid antibodies</span><span class="headingEndMark"> — </span>Antiphospholipid syndrome (APS) is associated with the development of severe early preeclampsia. Prophylaxis with both low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (LDA) and prophylactic-dose heparin starting at the end of the first trimester and continuing throughout pregnancy can decrease the rate of pregnancy complications (including preeclampsia) and improve pregnancy outcome in patients with APS. (See  <a class="medical medical_review" href="/d/html/6813.html" rel="external">"Antiphospholipid syndrome: Obstetric implications and management in pregnancy", section on 'Management of APS during pregnancy'</a>.)</p><p>Screening the general obstetric population for antiphospholipid antibodies is not useful. Candidates for laboratory testing for antiphospholipid antibodies (aPL), such as those with an unexplained stillbirth or stillbirth related to growth restriction or severe preeclampsia or other evidence of placental insufficiency, are described separately  (<a class="graphic graphic_table graphicRef104569" href="/d/graphic/104569.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/4678.html" rel="external">"Diagnosis of antiphospholipid syndrome", section on 'When to suspect the diagnosis'</a> and  <a class="medical medical_review" href="/d/html/4678.html" rel="external">"Diagnosis of antiphospholipid syndrome", section on 'Diagnostic evaluation'</a>.) </p><p class="headingAnchor" id="H14361831"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109729.html" rel="external">"Society guideline links: Hypertensive disorders of pregnancy"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk assessment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>History and physical examination</strong> – Pregnant individuals should be evaluated early in pregnancy for risk factors for preeclampsia. In the United States, the US Preventive Services Task Force criteria for patients at high risk of developing preeclampsia are commonly used for quantifying risk and selecting candidates for low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (LDA) prophylaxis. (See <a class="local">'Identify high-risk pregnancies early in gestation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of laboratory and imaging tests</strong> – A wide variety of laboratory and imaging tests have been proposed to distinguish individuals who will develop preeclampsia from those who will not. Systematic reviews of studies that evaluated clinically available tests have generally concluded that these tests were not sufficiently accurate for screening the general obstetric population and that the overall methodologic quality of available studies was generally poor. For this reason, we agree with American College of Obstetricians and Gynecologists' recommendations for taking a detailed medical history to assess a patient's risks for developing preeclampsia but not using laboratory and imaging screening tests (including uterine artery Doppler velocimetry and serum biomarkers such as pro- and anti-angiogenic factors). (See <a class="local">'Screening tests'</a> above.)</p><p></p><p class="bulletIndent2"><strong>Role of risk prediction tests</strong> – Specific maternal characteristics, Doppler ultrasound findings, and biomarkers in blood are associated with an increased risk of preeclampsia. Multiple investigators have used these variables in logistic regression analysis to create tools to predict an individual's risk of developing preeclampsia while they are still early in pregnancy. We do not use these tools because they have low-positive predictive values, thus many patients will be made anxious and treated unnecessarily, and methodologic deficiencies are common, which limit their reliability and validity. (See <a class="local">'Risk prediction models'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk modification</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most risk factors for preeclampsia are not modifiable; avoiding obesity and excessive gestational weight gain are notable exceptions. (See <a class="local">'Interventions to reduce risk'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>LDA</strong> is the only drug for which there is some evidence of benefit in reducing the risk of preeclampsia when administered throughout the second and third trimesters to patients at high risk for developing the disease. For low-risk patients, available evidence does not support use of LDA for prevention of preeclampsia, but a modest (approximately 10 percent) reduction in the risk of preeclampsia and its sequelae (growth restriction, preterm birth) is possible for those at moderate-to-high risk. (See <a class="local">'Interventions to reduce risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prenatal care</strong> – For patients who are at high risk of developing preeclampsia, establishing gestational age, baseline blood pressure, and baseline laboratory values including platelet count, creatinine concentration, liver function tests, and urinary protein estimation early in pregnancy can be helpful later in gestation in distinguishing preeclampsia from underlying disorders associated with similar clinical and laboratory findings. (See <a class="local">'Prenatal care for patients identified as high risk'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Angeli F, Angeli E, Reboldi G, Verdecchia P. Hypertensive disorders during pregnancy: clinical applicability of risk prediction models. J Hypertens 2011; 29:2320.</a></li><li><a class="nounderline abstract_t">Myatt L, Clifton RG, Roberts JM, et al. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol 2012; 119:1234.</a></li><li><a class="nounderline abstract_t">Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol 2020; 135:e237. Reaffirmed 2023.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement. JAMA 2017; 317:1661.</a></li><li><a class="nounderline abstract_t">Slade LJ, Mistry HD, Bone JN, et al. American College of Cardiology and American Heart Association blood pressure categories-a systematic review of the relationship with adverse pregnancy outcomes in the first half of pregnancy. Am J Obstet Gynecol 2023; 228:418.</a></li><li><a class="nounderline abstract_t">Sisti G, Fochesato C, Elkafrawi D, et al. Is blood pressure 120-139/80-89 mmHg before 20 weeks a risk factor for hypertensive disorders of pregnancy? A meta-analysis. Eur J Obstet Gynecol Reprod Biol 2023; 284:66.</a></li><li><a class="nounderline abstract_t">Henderson JT, Thompson JH, Burda BU, Cantor A. Preeclampsia Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2017; 317:1668.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 326:1186.</a></li><li class="breakAll">https://www.nice.org.uk/guidance/qs35/chapter/quality-statement-2-antenatal-assessment-of-pre-eclampsia-risk#what-the-quality-statement-means-for-service-providers-healthcare-practitioners-and-commissioners-2 (Accessed on March 30, 2018).</li><li><a class="nounderline abstract_t">Conde-Agudelo A, Romero R. SARS-CoV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis. Am J Obstet Gynecol 2022; 226:68.</a></li><li><a class="nounderline abstract_t">Milne F, Redman C, Walker J, et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ 2005; 330:576.</a></li><li class="breakAll">Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guideline No. 307. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: Executive summary. http://sogc.org/wp-content/uploads/2014/05/gui307CPG1405Erev.pdf (Accessed on July 27, 2016).</li><li><a class="nounderline abstract_t">Bartsch E, Medcalf KE, Park AL, et al. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ 2016; 353:i1753.</a></li><li><a class="nounderline abstract_t">Leslie K, Thilaganathan B, Papageorghiou A. Early prediction and prevention of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol 2011; 25:343.</a></li><li><a class="nounderline abstract_t">Allotey J, Snell KI, Smuk M, et al. Validation and development of models using clinical, biochemical and ultrasound markers for predicting pre-eclampsia: an individual participant data meta-analysis. Health Technol Assess 2020; 24:1.</a></li><li><a class="nounderline abstract_t">Liu Y, Meng Q. Risk of gestational hypertension and preeclampsia in pregnant women with new onset blood pressure of 120-129/≤89 mmHg: a meta-analysis of prospective studies. Hypertens Pregnancy 2022; 41:1.</a></li><li><a class="nounderline abstract_t">Chappell LC, Tucker KL, Galal U, et al. Effect of Self-monitoring of Blood Pressure on Blood Pressure Control in Pregnant Individuals With Chronic or Gestational Hypertension: The BUMP 2 Randomized Clinical Trial. JAMA 2022; 327:1666.</a></li><li><a class="nounderline abstract_t">Tucker KL, Mort S, Yu LM, et al. Effect of Self-monitoring of Blood Pressure on Diagnosis of Hypertension During Higher-Risk Pregnancy: The BUMP 1 Randomized Clinical Trial. JAMA 2022; 327:1656.</a></li><li><a class="nounderline abstract_t">Haugen M, Brantsæter AL, Winkvist A, et al. Associations of pre-pregnancy body mass index and gestational weight gain with pregnancy outcome and postpartum weight retention: a prospective observational cohort study. BMC Pregnancy Childbirth 2014; 14:201.</a></li><li><a class="nounderline abstract_t">Cnossen JS, ter Riet G, Mol BW, et al. Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal. Acta Obstet Gynecol Scand 2009; 88:758.</a></li><li><a class="nounderline abstract_t">Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004; 104:1367.</a></li><li><a class="nounderline abstract_t">Briceño-Pérez C, Briceño-Sanabria L, Vigil-De Gracia P. Prediction and prevention of preeclampsia. Hypertens Pregnancy 2009; 28:138.</a></li><li><a class="nounderline abstract_t">Meads CA, Cnossen JS, Meher S, et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 2008; 12:iii.</a></li><li><a class="nounderline abstract_t">Townsend R, Khalil A, Premakumar Y, et al. Prediction of pre-eclampsia: review of reviews. Ultrasound Obstet Gynecol 2019; 54:16.</a></li><li><a class="nounderline abstract_t">Snell KIE, Allotey J, Smuk M, et al. External validation of prognostic models predicting pre-eclampsia: individual participant data meta-analysis. BMC Med 2020; 18:302.</a></li><li><a class="nounderline abstract_t">Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet 2019; 145 Suppl 1:1.</a></li><li><a class="nounderline abstract_t">Myatt L. The prediction of preeclampsia: the way forward. Am J Obstet Gynecol 2022; 226:S1102.</a></li><li><a class="nounderline abstract_t">Chaemsaithong P, Sahota DS, Poon LC. First trimester preeclampsia screening and prediction. Am J Obstet Gynecol 2022; 226:S1071.</a></li><li><a class="nounderline abstract_t">Giguère Y, Charland M, Bujold E, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem 2010; 56:361.</a></li><li><a class="nounderline abstract_t">Brunelli VB, Prefumo F. Quality of first trimester risk prediction models for pre-eclampsia: a systematic review. BJOG 2015; 122:904.</a></li><li><a class="nounderline abstract_t">Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672.</a></li><li><a class="nounderline abstract_t">Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005; 46:1077.</a></li><li><a class="nounderline abstract_t">Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17:3.</a></li><li><a class="nounderline abstract_t">Chaiworapongsa T, Romero R, Tarca AL, et al. A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia. Am J Obstet Gynecol 2010; 202:550.e1.</a></li><li><a class="nounderline abstract_t">Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649.</a></li><li><a class="nounderline abstract_t">Wolf M, Shah A, Lam C, et al. Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol 2005; 193:16.</a></li><li><a class="nounderline abstract_t">Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12:642.</a></li><li><a class="nounderline abstract_t">Luft FC. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrol Dial Transplant 2006; 21:3052.</a></li><li><a class="nounderline abstract_t">AbdAlla S, Lother H, el Massiery A, Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001; 7:1003.</a></li><li><a class="nounderline abstract_t">Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355:992.</a></li><li><a class="nounderline abstract_t">Moore Simas TA, Crawford SL, Solitro MJ, et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007; 197:244.e1.</a></li><li><a class="nounderline abstract_t">Robinson CJ, Johnson DD. Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol 2007; 197:174.e1.</a></li><li><a class="nounderline abstract_t">Chaemsaithong P, Gil MM, Chaiyasit N, et al. Accuracy of placental growth factor alone or in combination with soluble fms-like tyrosine kinase-1 or maternal factors in detecting preeclampsia in asymptomatic women in the second and third trimesters: a systematic review and meta-analysis. Am J Obstet Gynecol 2023; 229:222.</a></li><li><a class="nounderline abstract_t">Levine RJ, Thadhani R, Qian C, et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005; 293:77.</a></li><li><a class="nounderline abstract_t">Levine RJ, Hauth JC, Curet LB, et al. Trial of calcium to prevent preeclampsia. N Engl J Med 1997; 337:69.</a></li><li><a class="nounderline abstract_t">Poon LC, Nicolaides KH. First-trimester maternal factors and biomarker screening for preeclampsia. Prenat Diagn 2014; 34:618.</a></li><li><a class="nounderline abstract_t">Farina A. Biophysical markers for abnormal placentation: first and/or second trimester. Prenat Diagn 2014; 34:628.</a></li><li><a class="nounderline abstract_t">Goetzinger KR, Odibo AO. Screening for abnormal placentation and adverse pregnancy outcomes with maternal serum biomarkers in the second trimester. Prenat Diagn 2014; 34:635.</a></li><li><a class="nounderline abstract_t">Halscott TL, Ramsey PS, Reddy UM. First trimester screening cannot predict adverse outcomes yet. Prenat Diagn 2014; 34:668.</a></li><li><a class="nounderline abstract_t">Martin A, Krishna I, Badell M, Samuel A. Can the quantity of cell-free fetal DNA predict preeclampsia: a systematic review. Prenat Diagn 2014; 34:685.</a></li><li><a class="nounderline abstract_t">Contro E, Bernabini D, Farina A. Cell-Free Fetal DNA for the Prediction of Pre-Eclampsia at the First and Second Trimesters: A Systematic Review and Meta-Analysis. Mol Diagn Ther 2017; 21:125.</a></li><li><a class="nounderline abstract_t">Qin S, Sun N, Xu L, et al. The Value of Circulating microRNAs for Diagnosis and Prediction of Preeclampsia: a Meta-analysis and Systematic Review. Reprod Sci 2022; 29:3078.</a></li><li><a class="nounderline abstract_t">Moufarrej MN, Vorperian SK, Wong RJ, et al. Early prediction of preeclampsia in pregnancy with cell-free RNA. Nature 2022; 602:689.</a></li><li><a class="nounderline abstract_t">Madala D, Maktabi MA, Sabbagh R, et al. Lower fetal fraction in clinical cell-free DNA screening results is associated with increased risk of hypertensive disorders of pregnancy. Prenat Diagn 2022; 42:1253.</a></li><li><a class="nounderline abstract_t">Cnossen JS, Morris RK, ter Riet G, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ 2008; 178:701.</a></li><li><a class="nounderline abstract_t">Kleinrouweler CE, Bossuyt PM, Thilaganathan B, et al. Value of adding second-trimester uterine artery Doppler to patient characteristics in identification of nulliparous women at increased risk for pre-eclampsia: an individual patient data meta-analysis. Ultrasound Obstet Gynecol 2013; 42:257.</a></li><li><a class="nounderline abstract_t">Velauthar L, Plana MN, Kalidindi M, et al. First-trimester uterine artery Doppler and adverse pregnancy outcome: a meta-analysis involving 55,974 women. Ultrasound Obstet Gynecol 2014; 43:500.</a></li><li><a class="nounderline abstract_t">Chien PF, Arnott N, Gordon A, et al. How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. BJOG 2000; 107:196.</a></li><li><a class="nounderline abstract_t">Papageorghiou AT, Yu CK, Nicolaides KH. The role of uterine artery Doppler in predicting adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2004; 18:383.</a></li><li><a class="nounderline abstract_t">Yu CK, Smith GC, Papageorghiou AT, et al. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol 2005; 193:429.</a></li><li><a class="nounderline abstract_t">Myatt L, Clifton RG, Roberts JM, et al. The utility of uterine artery Doppler velocimetry in prediction of preeclampsia in a low-risk population. Obstet Gynecol 2012; 120:815.</a></li><li class="breakAll">https://fetalmedicine.org/research/assess/preeclampsia (Accessed on February 21, 2018).</li><li><a class="nounderline abstract_t">Mosimann B, Amylidi-Mohr SK, Surbek D, Raio L. FIRST TRIMESTER SCREENING FOR PREECLAMPSIA - A SYSTEMATIC REVIEW. Hypertens Pregnancy 2020; 39:1.</a></li><li><a class="nounderline abstract_t">Foster AB, Park F, Hyett J. Do first-trimester screening algorithms for preeclampsia aligned to use of preventative therapies reduce the prevalence of pre-term preeclampsia: A systematic review and meta-analysis. Prenat Diagn 2023; 43:950.</a></li><li><a class="nounderline abstract_t">Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med 2017; 377:613.</a></li><li><a class="nounderline abstract_t">Guy GP, Leslie K, Diaz Gomez D, et al. Implementation of routine first trimester combined screening for pre-eclampsia: a clinical effectiveness study. BJOG 2021; 128:149.</a></li><li><a class="nounderline abstract_t">Gant NF, Daley GL, Chand S, et al. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 1973; 52:2682.</a></li><li><a class="nounderline abstract_t">Dekker GA, Makovitz JW, Wallenburg HC. Prediction of pregnancy-induced hypertensive disorders by angiotensin II sensitivity and supine pressor test. Br J Obstet Gynaecol 1990; 97:817.</a></li><li><a class="nounderline abstract_t">Gant NF, Chand S, Worley RJ, et al. A clinical test useful for predicting the development of acute hypertension in pregnancy. Am J Obstet Gynecol 1974; 120:1.</a></li><li><a class="nounderline abstract_t">Tomoda S, Kitanaka T, Ogita S, Hidaka A. Prediction of pregnancy-induced hypertension by isometric exercise. Asia Oceania J Obstet Gynaecol 1994; 20:249.</a></li><li><a class="nounderline abstract_t">Baker PN, Johnson IR. The use of the hand-grip test for predicting pregnancy-induced hypertension. Eur J Obstet Gynecol Reprod Biol 1994; 56:169.</a></li><li><a class="nounderline abstract_t">Cnossen JS, de Ruyter-Hanhijärvi H, van der Post JA, et al. Accuracy of serum uric acid determination in predicting pre-eclampsia: a systematic review. Acta Obstet Gynecol Scand 2006; 85:519.</a></li><li><a class="nounderline abstract_t">Thangaratinam S, Ismail KM, Sharp S, et al. Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. BJOG 2006; 113:369.</a></li><li><a class="nounderline abstract_t">Urato AC, Bond B, Craigo SD, et al. Admission uric acid levels and length of expectant management in preterm preeclampsia. J Perinatol 2012; 32:757.</a></li><li><a class="nounderline abstract_t">Dizon-Townson D, Miller C, Sibai B, et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol 2005; 106:517.</a></li><li><a class="nounderline abstract_t">Silver RM, Zhao Y, Spong CY, et al. Prothrombin gene G20210A mutation and obstetric complications. Obstet Gynecol 2010; 115:14.</a></li></ol></div><div id="topicVersionRevision">Topic 6750 Version 62.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22075955" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hypertensive disorders during pregnancy: clinical applicability of risk prediction models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22617589" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : First-trimester prediction of preeclampsia in nulliparous women at low risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32443079" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28444286" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36241079" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : American College of Cardiology and American Heart Association blood pressure categories-a systematic review of the relationship with adverse pregnancy outcomes in the first half of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36934679" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Is blood pressure 120-139/80-89 mmHg before 20 weeks a risk factor for hypertensive disorders of pregnancy? A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28444285" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Preeclampsia Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34581729" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34581729" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34302772" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : SARS-CoV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15760998" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15760998" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27094586" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21376671" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Early prediction and prevention of pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33336645" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Validation and development of models using clinical, biochemical and ultrasound markers for predicting pre-eclampsia: an individual participant data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34791972" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Risk of gestational hypertension and preeclampsia in pregnant women with new onset blood pressure of 120-129/≤89 mmHg: a meta-analysis of prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35503345" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of Self-monitoring of Blood Pressure on Blood Pressure Control in Pregnant Individuals With Chronic or Gestational Hypertension: The BUMP 2 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35503346" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of Self-monitoring of Blood Pressure on Diagnosis of Hypertension During Higher-Risk Pregnancy: The BUMP 1 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24917037" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Associations of pre-pregnancy body mass index and gestational weight gain with pregnancy outcome and postpartum weight retention: a prospective observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19488883" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15572504" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : World Health Organization systematic review of screening tests for preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19437225" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prediction and prevention of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18331705" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30267475" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prediction of pre-eclampsia: review of reviews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33131506" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : External validation of prognostic models predicting pre-eclampsia: individual participant data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31111484" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33785181" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The prediction of preeclampsia: the way forward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32682859" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : First trimester preeclampsia screening and prediction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20044446" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25761437" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Quality of first trimester risk prediction models for pre-eclampsia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764923" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Circulating angiogenic factors and the risk of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16230516" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15804781" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20510958" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12618519" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16021053" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16751767" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Soluble endoglin contributes to the pathogenesis of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16870672" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533702" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16957146" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17826405" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Angiogenic factors for the prediction of preeclampsia in high-risk women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17689640" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Soluble endoglin as a second-trimester marker for preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36990308" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Accuracy of placental growth factor alone or in combination with soluble fms-like tyrosine kinase-1 or maternal factors in detecting preeclampsia in asymptomatic women in the second and third trimesters: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15632339" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Urinary placental growth factor and risk of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9211675" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Trial of calcium to prevent preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24764257" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : First-trimester maternal factors and biomarker screening for preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24711072" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Biophysical markers for abnormal placentation: first and/or second trimester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24687572" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Screening for abnormal placentation and adverse pregnancy outcomes with maternal serum biomarkers in the second trimester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24855016" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : First trimester screening cannot predict adverse outcomes yet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24852111" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Can the quantity of cell-free fetal DNA predict preeclampsia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27838884" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Cell-Free Fetal DNA for the Prediction of Pre-Eclampsia at the First and Second Trimesters: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34817849" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The Value of Circulating microRNAs for Diagnosis and Prediction of Preeclampsia: a Meta-analysis and Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35140405" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Early prediction of preeclampsia in pregnancy with cell-free RNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35943975" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Lower fetal fraction in clinical cell-free DNA screening results is associated with increased risk of hypertensive disorders of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18332385" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23417857" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Value of adding second-trimester uterine artery Doppler to patient characteristics in identification of nulliparous women at increased risk for pre-eclampsia: an individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24339044" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : First-trimester uterine artery Doppler and adverse pregnancy outcome: a meta-analysis involving 55,974 women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10688503" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15183134" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The role of uterine artery Doppler in predicting adverse pregnancy outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098866" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22996099" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The utility of uterine artery Doppler velocimetry in prediction of preeclampsia in a low-risk population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22996099" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The utility of uterine artery Doppler velocimetry in prediction of preeclampsia in a low-risk population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31670986" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : FIRST TRIMESTER SCREENING FOR PREECLAMPSIA - A SYSTEMATIC REVIEW.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37277892" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Do first-trimester screening algorithms for preeclampsia aligned to use of preventative therapies reduce the prevalence of pre-term preeclampsia: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28657417" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32613730" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Implementation of routine first trimester combined screening for pre-eclampsia: a clinical effectiveness study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4355997" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A study of angiotensin II pressor response throughout primigravid pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2242367" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prediction of pregnancy-induced hypertensive disorders by angiotensin II sensitivity and supine pressor test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4367310" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A clinical test useful for predicting the development of acute hypertension in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7811189" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prediction of pregnancy-induced hypertension by isometric exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7821488" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The use of the hand-grip test for predicting pregnancy-induced hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16755708" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Accuracy of serum uric acid determination in predicting pre-eclampsia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16553648" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22193928" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Admission uric acid levels and length of expectant management in preterm preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135581" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20027028" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Prothrombin gene G20210A mutation and obstetric complications.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
